About Us
Mission RNAi Management Team Board of Directors Scientific Advisory Board
Scientific Advisory Board
Dr. Hanahan is an American Cancer Society Research Professor in the Department of Biochemistry & Biophysics at the University of California, San Francisco. In 2007 he was elected as a fellow in the American Academy of Arts & Sciences. Dr. Hanahan received a B.S. in Physics from MIT, and a Ph D in Biophysics from Harvard, where he was a Harvard Junior Fellow. In the mid-1980’s Dr. Hanahan produced some of the first transgenic ‘oncomice’, genetically engineered to develop organ-specific cancers. He discovered, in collaboration with Dr. Judah Folkman, the ‘angiogenic switch’ which is activated to produce new blood vessels in early stage neoplastic lesions preceding overt tumors. Dr. Hanahan has authored more than 150 publications, including a number of influential perspectives. At UCSF, Dr. Hanahan is the leader of the Mouse Models of Cancer Program in the Comprehensive Cancer Center, and a member of the Diabetes Center. He has used those cancer models both to investigate the multistage pathways that govern tumor formation and progression, and to explore the benefits of targeted therapies at different stages of cancer progression.
Dr. Kay is the Director of the Program in Human Gene Therapy and the Dennis Farrey Family Professor in the Departments of Pediatrics and Genetics at Stanford University. He received a Ph.D. in Developmental Genetics, and M.D. from Case Western Reserve in Cleveland, Ohio. He did his fellowship in medical genetics and biochemical genetics at Baylor College of Medicine. Before coming to Stanford, Dr. Kay was at the University of Washington as Associate Professor in the Departments of Medicine, with adjuncts in Pediatrics, Biochemistry and Pathology. Dr. Kay has received many awards and was on the founding board of directors of the American Society for Gene Therapy and served as the Society's President in 2005-2006.
Dr. Kay's research has lead to over 150 scientific publications in various leading journals. His laboratory was the first to demonstrate RNAi activity in whole non-embryonic mammals, and RNAi-mediated inhibition of viral hepatitis B replication in animals. His work continues on defining clinically-relevant gene therapy approaches and establishing some of the molecular limits of RNAi in vivo.
Dr. Kuo is currently an Associate Professor of Medicine in the Hematology Division at Stanford University School of Medicine. His laboratory investigates mechanisms of angiogenesis with an emphasis on vascular G-protein coupled receptors, secreted molecules and microRNA, using knockout, transgenic, adenoviral and zebrafish approaches.
Dr. Kuo received his A.B. from Harvard College and his M.D. and Ph.D. degree from Stanford University. He performed postdoctoral research at Harvard Children’s Hospital with Judah Folkman and Richard Mulligan, before starting his position at Stanford in 2001. Dr. Kuo has published extensively in journals including Nature, Science, Cell and Nature Medicine and is an inventor on numerous issued and pending patents. He is principal investigator on numerous NIH grants, has received junior faculty awards from the Burroughs Wellcome and Kimmel Foundations, and has been elected to the American Society for Clinical Investigation.
Professor Daniel W. Pack is an Associate Professor of Chemical and Biomolecular Engineering at the University of Illinois, Urbana-Champaign. He graduated from the University of Illinois with a B.S. degree in Chemical Engineering in 1990 and earned his Ph.D., also in Chemical Engineering, at the California Institute of Technology in 1997. Prof. Pack was a NIH post-doctoral fellow with Robert Langer at the Massachusetts Institute of Technology during 1997-1998 before starting his career at UIUC in 1999. Prof. Pack won a Faculty Early Career Development (CAREER) award from the NSF in 2002, and he was a Beckman Fellow at the Center for Advanced Studies at UIUC in 2004-2005. Prof. Pack also serves on the editorial board of the Journal of Controlled Release. He has authored more than 50 peer-reviewed publications, abstracts and patents. Prof. Pack's research focuses on design of novel gene delivery vectors, in particular by developing quantitative understanding of their intracellular trafficking mechanisms. His group has designed several new classes of polymeric vectors, as well as "hybrid" vectors comprising both viral and synthetic components.
Dr Seymour has been the Co-Director of the Investigational New Drug Program at the NCI Canada Clinical Trial Group since 1996; she also serves as the Director of the Audit and Monitoring Group of NCIC CTG, is a staff oncologist at the Cancer Centre of Southeastern Ontario and is a Professor of Oncology at Queens University, Kingston Ontario. She graduated from the University of the Witwatersrand in 1978 and subsequently completed specialist training in Internal Medicine, Clinical Hematology, and Medical Oncology. In her current role, her primary responsibilities are Phase I and II studies of novel compounds, as well as research into lung malignancies. She is the principal investigator and co-investigator on numerous grants for clinical research and training. Dr Seymour has served on many provincial, national and international committees as well as review and grants panels, including Cancer Care Ontario, National Cancer Institute of Canada, National Cancer Institute, and the American Society of Clinical Oncology as well as Health Canada. She has published over 100 peer-reviewed manuscripts.
Dr. Wagner is Professor of Pharmaceutical Biotechnology and current Director of the Center for Drug Research at the LMU, University of Munich, Germany. He is also member of the Center of Nanoscience (CeNS) and coordinator of the area “Programmed drug delivery” of the cluster of excellence Nanosystems Initiative Munich (NIM). Dr. Wagner received a Ph D in Organic Chemistry from Technical University of Vienna. After a postdoctoral stay with Albert Eschenmoser at Federal School of Technology (ETH) Zurich, Switzerland, he was group leader at the Institute of Molecular Pathology (IMP) and the Vienna University Biocenter, Vienna, Austria. During that time he developed receptor-mediated gene delivery and artificial virus-like gene transfer systems.
Dr. Wagner was Director for Cancer Vaccines and Gene Therapy at Boehringer Ingelheim Austria, and in 1996 FC Donders Professor for Biopharmaceutical Sciences at Utrecht University, The Netherlands, before joining the LMU in 2001. Dr. Wagner has authored more than 200 publications and more than 15 patents in the area of gene delivery and oncology. He is Editor of Current Opinion in Molecular Therapeutics, and Associate Editor of the journals Molecular Therapy and Journal of Gene Medicine.
|
